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limiting and how to optimize the plan. Without this 
approach, there was an increase risk of severe, even fatal 
esophagus toxicity for the patient. 
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Purpose/Objective: In England in 2012/2013, there was a 
strong Government drive to increase the availability of 
IMRT/VMAT treatment for appropriate patient groups. Up to 
September 2013, prostate and seminal vesicle patients (PSV) 
at this centre were treated with a 3 field forward planned 
IMRT technique (fpIMRT) using 10MV photons (with target and 
OAR doses based on the CHHiP trial using a 3 dose level 
target PTV1, 2 and 3). This was replaced with a 6MV single 
arc VMAT technique. In both cases, treatment delivery was 
with Elekta Synergy accelerators fitted with MLCi (1cm leaf 
width). This investigation looked at the organ at risk (OAR) 
doses achieved using both techniques. In introducing this new 
technique, the minimum target dose to PTV1 (PSV + a 
uniform margin of 1cm) was also increased in line with 
another UK department who provided VMAT implementation 
mentoring. This audit assessed the effect of the treatment 
technique change along with PTV1 dose escalation and 
identified whether the acute side effects seen during 
treatment were affected by this technique and dose change. 
Materials and Methods: Philips Pinnacle V9.8 is routinely 
used to contour and plan all PSV patients. DVH analysis was 
performed to extract OAR doses and PTV doses for 39 
patients who were planned using the fpIMRT technique and 
49 patients planned using the VMAT technique. Microsoft 
Excel 2010 was used to collate and analyse the data. The 
RTOG scoring system was used during treatment to assess 6 
common acute side effects for this group of patients. 
Results: All dose constraints were met consistently met using 
a forward planned technique. However the introduction of 
VMAT planning allowed an escalation to the achievable PTV1 
minimum dose within those same dose constraints. The RTOG 
scores during treatment for six common acute side effects for 
this group of patients showed that whilst the difference in 
technique has not decreased the side effects seen by a 
statistically significant amount, the average score for each 
side effect were lower for the patients treated with VMAT, 
even with the higher dose to PTV1. 
The low dose bath effect to the rectum of the VMAT planning 
technique is evident in the analysis of the dose constraints, 
with the average V30Gy at 76.2% and the average V40Gy at 
64.6%, compared with V30Gy: 55.8%, V40Gy: 43.4% for 
fpIMRT. These dose constraints were not classified as 
mandatory in the CHHiP clinical trial or in this department's 
clinical protocol. The mandatory high dose (65Gy, 70Gy, 
74Gy) constraints demonstrate a reduction in the amount of 
rectum within these dose regions of the prostate treatment 
with the implementation of VMAT. 
 
Conclusions: Implementation of a VMAT technique for the 
treatment of PSV has resulted in an increase of dose 
uniformity of the PTVs by increasing the achievable minimum 
PTV1 dose and reducing the high dose level received by the 
rectum. Further work will investigate whether there is scope 
within those same OAR constraints to escalate PTV doses 
further if clinically rquired. 
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Purpose/Objective:  tolerance and toxicity of adiuvant 
exclusive vaginal High Dose Rate Brachytherapy (HDR_BT) in 
patients with endometrial cancer. 
Materials and Methods: A total of 30 patients (pts), median 
age 70 years old, were treated by postoperative HDR vaginal 
cuff Brachytherapy. Patients underwent hysterecomy for 
endometrial cancer. Staging and grading according FIGO were 
8-IA, 18 IB, 3 II, 1-IIIA; 2-G1, 18-G2, 10-G3. HDR-BRT was 
performed using vaginal cylindrical applicators applied to the 
patients who received five fractions of 600cGy to a total dose 
of 3000 cGy prescribed to the 0.5 from the applicator's 
surface. Computed Tomography (CT) simulation was 
performed with CT slices thickness of 5 mm. Proximal 3-3.5 
cm of the vagina were treated. Bowels are more than bladder 
very radiosensitive and so to prevent bowels toxicity, all 
patients were asked to consume from 250 ml to 400 ml of 
water 30 minutes before CT scan and before treatment and 
empty rectum by means a selfie applied rectal enema. Acute 
and late Gastrointestinal (GI) and Genitourinary (GU) 
toxicities were investigate according RTOG Toxicity scale. 
